Introduction
Methods
Study population
Clinical evaluation
Outcome
Statistical analysis
Results
Study population
Definite ARVD/C (n = 29) | |
Demographics
| |
Male | 16 (55) |
Age at presentation (years) | 59.0 ± 5.8 |
Proband | 16 (55) |
Mutation carrier | 21 (72) |
Plakophilin-2 | 14 (48) |
Phospholamban | 7 (24) |
Clinical phenotype at last follow-up
| |
Age at diagnosis (years) | 59.9 ± 6.7 |
Repolarisation TFC | 20 (69) |
T-wave inversion V1–3 | 16 (55) |
T-wave inversion V1–2 | 2 (7) |
T-wave inversion V4–6 | 2 (7) |
T-wave inversion V1–4 with complete RBBB | 0 (0) |
Depolarisation TFC | 21 (72) |
Epsilon wave | 5 (17) |
>TAD | 17 (59) |
Late potentials | 8/18 (44) |
Arrhythmia TFC | 28 (97) |
Holter abnormal | 16/21 (76) |
PVC count; median [IQR] | 2056 [560–5952] |
LBBB superior axis VT | 13 (45) |
LBBB VT | 15 (52) |
Structural TFC | 24 (83) |
Major | 21 (73) |
Minor | 3 (10) |
TFC points; median [IQR] | 6 [5–8] |
Clinical evaluation
Ventricular arrhythmia
VT (n = 15) | No VT (n = 14) |
p value
| |
Demographics
| |||
Male | 11(73) | 5 (36) | 0.042 |
Proband | 13 (87) | 3 (21) | <0.001 |
Mutation carrier | 10 (67) | 11 (79) | 0.682 |
Plakophilin-2 | 7 (47) | 7 (50) | 0.862 |
Phospholamban | 3 (20) | 4 (29) | 0.682 |
Mode of presentation | |||
Family screening Symptomatic Sustained VT SCA SCD | 0 (0) 3 (20) 12 (80) 0 (0) 0 (0) | 10 (71) 4 (29) 0 (0) 0 (0) 0 (0) | <0.001 0.682 <0.001 – – |
Clinical phenotype at last follow-up
| |||
Age at diagnosis (years) | 62.5 ± 9.7 | 60.9 ± 6.4 | 0.623 |
T-wave inversion V1–3 | 7 (47) | 9 (64) | 0.340 |
T-wave inversion V1–2 | 2 (13) | 0 (0) | 0.483 |
T-wave inversion V4–6 | 0 (0) | 2 (14) | 0.224 |
T-wave inversion V1–4 with complete RBBB | 0 (0) | 0 (0) | – |
Epsilon wave | 4 (27) | 1 (7) | 0.330 |
>TAD | 9 (60) | 8 (57) | 0.876 |
Late potentials | 5/11 (45) | 3/7 (43) | 1.000 |
Holter monitor abnormal | 5/8 (63) | 11/13 (85) | 0.325 |
PVC count; median [IQR] | 919 [341–2095] | 3108 [1205–6141] | 0.205 |
Major structural TFC | 13 (87) | 8 (57) | 0.109 |
Minor structural TFC | 1 (7) | 2 (14) | 0.598 |
TFC points; median [IQR] | 6[5–7] | 6 [5–8] | 0.506 |
Ventricular arrhythmia during follow-up
Patient #1 | Patient #2 | Patient #3 | |
---|---|---|---|
Demographics
| |||
Sex | M | M | M |
Age at time of diagnosis (years) | 55 | 69 | 59 |
Proband | Yes | Yes | Yes |
Pathogenic mutation | – | – | + (PKP2) |
Sustained arrhythmia characteristics
| |||
Age at time of arrhythmia | 55 | 71 | 59 |
Morphology | LBBB | LBBB | LBBB |
Axis | Superior | Superior | Inferior |
Cycle length (ms) | 240 | 231 | 429 |
Documentation | Walking | Cardiac stress test | Holter monitoring |
Clinical phenotype at time of sustained arrhythmia
| |||
Repolarisation TFC | None | None | TWI V1–4 (major) |
Depolarisation TFC | None | Late potentials (minor) | Epsilon wave (major) |
Arrhythmia TFC | LBBB superior axis VT (major) | 560 PVCs/24 h (minor), LBBB superior axis VT (major) | 11180 PVCs/24 h (minor), LBBB inferior axis VT (minor) |
Structural TFC | RV aneurysm + reduced RV function (major) | RV aneurysm + reduced RV function (major) | RV aneurysm + reduced RV function (major) |
Family history TFC | None | None | Major |
TFC points at time of arrhythmic event | 4 | 5 | 8 |
Clinical features
| |||
Symptoms prior to event | Exercise-induced syncope, presyncope | Palpitations | Palpitations |
Medication at time of arrhythmia | Perindopril 8 mg, Hydrochlorothiazide 25 mg | Atenolol 25 mg | Acenocoumarola, Enalapril 20 mg, Simvastatin 40 mg |
Relevant comorbidity | Hypertension | – | Ischaemic CVA |
Coronary angiography | Normal | Normal | Normal |